Dermapharm Holding Se · XETR:DMP

Dermapharm — H1 2020 Earnings Presentation

17 slides from Dermapharm's earnings presentation, Sep 9, 2020

  1. Slide 1: Investor and Analyst Conference Call H1 2020

    INVESTOR AND ANALYST CONFERENCE CALL H1 2020 Grünwald, 9 September 2020

  2. Slide 2: Disclaimer

    Disclaimer This publication includes statements, estimates, opinions and projections with respect to the anticipated future performance of Dermapharm Holding SE (together with its consolidated subsidiaries, “Dermapharm”) and such statements, estimates, opinions and projections (“Forward- Looking Sta

  3. Slide 3: Agenda

    AGENDA 1. Highlights H1 2020 2. Financial figures H12020 3. Outlook FY 2020 4. Q & A

  4. Slide 4: Agenda

    AGENDA 1. Highlights H1 2020 2. Financial figures H12020 3. Outlook FY 2020 4. Q & A

  5. Slide 5: Highlights H1 2020: Dermapharm's strategy proves resilience

    Highlights H1 2020: Dermapharm’s strategy proves resilience COVID-19: Our approach “made in Germany” pays off – constant ability to deliver supported by classification as critical infrastructure In-house development based on pipeline of > 50 ongoing development projects, four new product launches so

  6. Slide 6: Agenda

    AGENDA 1. Highlights H1 2020 2. Financial figures H1 2020 3. Outlook FY 2020 4. Q & A

  7. Slide 7: Dermapharm Group: Strong overall growth despite COVID-19 pandemic

    Dermapharm Group Strong overall growth despite COVID-19 pandemic Total Revenue (€m) EBITDA(1) (€m, adjusted) Comments EBITDA margin +13.5% YoY 27.0% 24.2% 378.2 Significant revenue growth of 13.5% to €378.2m, due to 333.2  consolidation of latest acquisition in H1 2020  organic growth in branded p

  8. Slide 8: Branded pharmaceuticals and other healthcare products

    Branded pharmaceuticals and other healthcare products Further growth expansion driven by integration of acquisition Revenue (€m) EBITDA(1) (€m, adjusted) Comments EBITDA Margin Revenues up by 21.2% to €212.1m +21.2% YoY 43.7% 37.6%  mainly based on consolidation of Fitvia and Allergopharma  lower

  9. Slide 9: Parallel import business

    Parallel import business Growth driven by COVID-19 resulting in higher demand and intact sources of supply Revenue (€m) EBITDA (€m) Comments EBITDA Margin +7.0% YoY 4.1% 4.1% Revenues increased by 7.0% to €126.7m  higher demand for parallel imported originator products was partly compensated in Q2

  10. Slide 10: Herbal extracts

    Herbal extracts Decreasing demand due to COVID-19 pandemic Revenue (€m) EBITDA(1) (€m, adjusted) Comments EBITDA Margin -1.0% YoY 28.4% 23.9% Revenues decreased by 1.0% to €39.4m, comprising Euromed 39.4  weak demand for herbal extracts in Q1 due to Corona pandemic could partly be compensated by hi

  11. Slide 11: Earnings before tax (Group EBT)

    Earnings before tax (Group EBT) Result increased due to M&A and business growth Earnings before tax (EBT)(1) (€m) Comments EBT Margin 16.5% 15.5%  EBT increased by 6.9% to €58.7m (unadjusted) resulting in a margin of 15.5% +6.9% YoY Mainly influenced by  lower depreciation and amortisation (€1.5m)

  12. Slide 12: Strong cash flows and cash conversion

    Strong cash flows and cash conversion Reflecting strong dedication to future growth Cash flow and cash conversion(1)(€m) Comments in % of Group EBITDA Cash conversion 49.3% 44.6%  CF from operating activities decrease mainly influenced  by increased active working capital in H1 2020 due to interna

  13. Slide 13: Balance sheet of Dermapharm Group

    Balance sheet of Dermapharm Group Balance Sheet as of 30 June 2020 (€m) Comments  Total assets increased to €1,202m (31 December 2019: €1,045m) 1,202 1,202  Non-current assets on rose to €806m (31 December 2019: €692m) driven by integration of Allergopharma Equity  Current assets increased to €39

  14. Slide 14: Agenda

    AGENDA 1. Highlights H1 2020 2. Financial figures H1 2020 3. Outlook FY 2020 4. Q & A

  15. Slide 15: Growth strategy on track and informing guidance 2020

    Growth strategy on track and informing guidance 2020 Revenues 2020 positive growth of 12-15% vs. previous year (€700.9m) EBITDA 2020 positive growth of 8-10% (adjusted) vs. previous year (€177.6m) Growth rates are based on organic growth supported by new launches of in-house developments. Guidance f

  16. Slide 16: Agenda

    AGENDA 1. Highlights FY 2019 2. Financial figures FY 2019 3. Outlook FY 2020 4. Q & A

  17. Slide 17: Investor contact

    Investor contact Britta Hamberger Investor Relations & Corporate Communications Dermapharm Holding SE E-Mail: ir@dermapharm.com Phone: +49 (0) 89 641 86 233

Dermapharm Holding — H1 2020 Earnings Presentation on 6ix